Quince Therapeutics, Inc.
QNCX
$1.05
$0.05956.01%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -56.83M | -53.26M | -53.12M | -30.28M | -31.39M |
| Total Depreciation and Amortization | 186.00K | 474.00K | 388.00K | 345.00K | 322.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.22M | 24.49M | 26.80M | 7.29M | 10.79M |
| Change in Net Operating Assets | -484.00K | -2.13M | -2.06M | -433.00K | 1.98M |
| Cash from Operations | -31.90M | -30.43M | -27.99M | -23.08M | -18.29M |
| Capital Expenditure | -257.00K | -148.00K | -102.00K | -63.00K | -160.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 0.00 | 90.00K |
| Cash Acquisitions | -- | -2.12M | -2.12M | -2.12M | -2.12M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 22.17M | 18.70M | 15.18M | -205.00K | -3.57M |
| Cash from Investing | 21.91M | 16.43M | 12.96M | -2.38M | -5.76M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | 0.00 | 0.00 | -6.00K |
| Issuance of Common Stock | 225.00K | 282.00K | 292.00K | 283.00K | 149.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.00M | -5.00M | -- | -- | -- |
| Cash from Financing | -4.78M | -4.72M | 292.00K | 283.00K | 143.00K |
| Foreign Exchange rate Adjustments | 231.00K | -240.00K | -25.00K | 276.00K | 80.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.54M | -18.96M | -14.76M | -24.90M | -23.83M |